Associate Professor Liz Musgrove
Cancer Institute NSW Fellow; Group Leader, Cancer Research Program, Garvan Institute of Medical Research; Conjoint Associate Professor, Faculty of Medicine, The University of New South Wales
Email: e.musgrove 'at' garvan.org.au
Research Group: Cell Cycle
Education
1991 PhD, The University of New South WalesÂ
1979 BSc (Hons), The University of New South Wales
Publications
Caldon CE, Swarbrick A, Lee CSL, Sutherland RL, Musgrove EA (2008). The HLH protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res 68: 3026-3036.Butt AJ, Sergio CM, Inman CK, Anderson LR, McNeil CM, Russell AJ, Nousch M, Preiss T, Biankin AV, Sutherland RL, Musgrove EA. (2008). The estrogen- and c-Myc target gene HSPC111 is overexpressed in breast cancer and associated with poor patient outcome. Breast Cancer Res 10: R28 (doi:10.1186/bcr1985).
Caldon CE, Lee CSL, Sutherland RL, Musgrove EA. (2008). Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that mediates effects on proliferation and differentiation. Oncogene 27: 126-138.
Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Cell cycle control on breast cancer cells. J Cell Biochem 2007; 97(2):261-274.
Swarbrick A, Akerfeldt MC, Lee CS, Sergio CM, Caldon CE, Hunter L-JK, Sutherland RL, Musgrove EA. Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene 2005; 24(3):381-389.
Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005; 12:S47-S59.
Kalish LH, Kwong RA, Cole IE, Gallagher R, Sutherland RL, Musgrove EA. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004; 10(22):7764-7774.
Carroll JS, Lynch DK, Swarbrick A, Renoir J-M, Sarcevic B, Daly RJ, Musgrove EA, Sutherland RL. p27Kip1 induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 2003; 63:4322-4326.
Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002; 62:3126-3131.
Areas of Interest
genetics, cell cycle control, helix-loop-helix proteins, breast cancer, cyclins, estrogen, oestrogenNews
Calculating how breast cancers will respond to tamoxifen
MEDIA RELEASE:
08 Sep 2008
A discovery by Garvan scientists should help clinicians decide which women with breast cancer will make good candidates for anti-oestrogen therapies, such as tamoxifen, and which will not.
